Skip to main content
. 2022 Jul 28;12:953780. doi: 10.3389/fcimb.2022.953780

Table 2.

The relationship among biofilm-forming ability of E. anophelis with antibiotic resistance pattern.

Biofilm formation ability Strong (n = 80) Moderate (n = 82) Weak (n = 35)
Antibiotics R No. (%) I No. (%) S No. (%) R No. (%) I No. (%) S No. (%) R No. (%) I No. (%) S No. (%)
Piperacillin 56 (70) 17 (21.25) 7 (8.75) 36 (43.9) 18 (21.95) 28 (34.15) 6 (17.14) 15 (42.86) 14 (40)
Piperacillin-tazobactam 29 (36.25) 38 (47.5) 13 (16.25) 24 (29.27) 21(25.61) 37(45.12) 4 (11.43) 14 (40) 17(48.57)
Ceftazidime 80 (100) 82 (100) 34 (97.14) 1 (2.86)
Cefepime 80 (100) 78 (95.12) 4 (4.88) 30 (85.71) 3 (8.57) 2 (5.72)
Imipenem 80 (100) 82 (100) 34 (97.14) 1(2.86)
Meropenem 80 (100) 82 (100) 33 (94.29) 2 (5.71)
Aztreonam 80 (100) 82 (100) 35 (100)
Gentamicin 74 (92.5) 5 (6.25) 1 (1.25) 70 (85.37) 8 (9.75) 4 (4.88) 30 (85.72) 3 (8.57) 2 (5.71)
Amikacin 67 (83.75) 10 (12.5) 3 (3.75) 64 (78.05) 13 (15.85) 5 (6.1) 23 (65.71) 8 (22.86) 4 (11.43)
Minocycline 80(100) 82(100) 35(100)
Doxycycline 2 (2.5) 78 (97.5) 1 (1.22) 4 (4.88) 77 (93.9) 1 (2.86) 34 (97.14)
Tetracycline 69 (86.25) 8 (10) 3 (3.75) 79 (96.34) 3 (3.66) 30 (85.71) 3 (8.57) 2 (5.72)
Tigecycline 10 (12.5) 44 (55) 26 (32.5) 17 (20.73) 37 (45.12) 28 (34.15) 3 (8.58) 16 (45.71) 16 (45.71)
Ciprofloxacin 18 (22.5) 25 (31.25) 37 (46.25) 28 (34.15) 19 (23.17) 35 (42.68) 7 (20) 5 (14.29) 23 (65.71)
Levofloxacin 14 (17.5) 66 (82.5) 21(25.61) 6 (7.32) 55 (67.07) 4 (11.43) 2 (5.71) 29 (82.86)
Trimethoprim-
sulfamethoxazole
80 (100) 80(97.56) 2 (2.44) 35(100)
Rifampin 3 (3.75) 1 (1.25) 76 (95) 6 (7.32) 1(1.22) 75 (91.46) 1(2.86) 34 (97.14)
Vancomycin 31 (38.75) 48 (60) 1 (1.25) 12 (14.63) 70 (85.37) 7 (20) 28 (80)
Chloramphenicol 37 (46.25) 37 (46.25) 6 (7.5) 53 (64.63) 27 (32.93) 2 (2.44) 23 (65.71) 9 (25.72) 3 (8.57)

R, resistant; S, susceptible; I, intermediate resistant.